Bluebird Bio, a biotech company with three approved gene therapies but no way of commercialising them, will be sold to private equity firms Carlyle and SK Capital Partners in a $29 million deal. Bluebird’s therapies offered rare disease treatments, including beta thalassemia and cerebral adrenoleukodystrophy; a third did not include the necessary financial cover of a PRV required to finance its intense manufacturing processes and was rejected three times by the FDA, leading to debt and restructuring. The sale could bring Bluebird up to $67 million more if the therapies reach a sales target.
Anne Arundel County Government Hit by Cyber Attack – Eye On Annapolis
Anne Arundel County Government was recently targeted by a cyber attack. This led to disruption in various services provided by the government. The attack affected
